An Open-Label, Single-Arm, Multicenter Phase II Study of E7080 (Lenvatinib) in Subjects With Advanced Endometrial Cancer and Disease Progression Following First-Line Chemotherapy
Phase of Trial: Phase II
Latest Information Update: 01 Feb 2017
At a glance
- Drugs Lenvatinib (Primary)
- Indications Endometrial cancer
- Focus Therapeutic Use
- Acronyms HOPE
- Sponsors Eisai Co Ltd
- 16 Apr 2016 Status changed from active, no longer recruiting to completed.
- 18 Apr 2014 Planned End Date changed from 1 Dec 2013 to 1 Aug 2014, as per ClinicalTrials.gov record.
- 13 Sep 2013 Planned end date changed from 1 Jun 2013 to 1 Dec 2013 as reported by ClinicalTrials.gov.